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Abstract—The purpose of this study was to compare 2 adaptive radiotherapy strategies with helical tomo-
therapy. A patient having mesothelioma with mediastinal nodes was treated using helical tomotherapy with
pretreatment megavoltage CT (MVCT) imaging. Gross tumor volumes (GTVs) were outlined on every MVCT
study. Two alternatives for adapting the treatment were investigated: (1) keeping the prescribed dose to the
targets while reducing the dose to the OARs and (2) escalating the target dose while maintaining the original level
of healthy tissue sparing. Intensity modulated radiotherapy (step-and-shoot IMRT) and 3D conformal radio-
therapy (3DCRT) plans for the patient were generated and compared. The primary lesion and nodal mass
regressed by 16.2% and 32.5%, respectively. Adapted GTVs and reduced planning target volume (PTV) margins
of 4 mm after 22 fractions decrease the planned mean lung dose by 19.4%. For dose escalation, the planned
prescribed doses may be increased from 50.0 to 58.7 Gy in PTV1 and from 60.0 to 70.5 Gy in PTV2. The
step-and-shoot IMRT plan was better in sparing healthy tissue but did not provide target coverage as well as the
helical tomotherapy plan. The 3DCRT plan resulted in a prohibitively high planned dose to the spinal cord.
MVCT studies provide information both for setup correction and plan adaptation. Improved healthy tissue
sparing and/or dose escalation can be achieved by adaptive planning. © 2009 American Association of Medical
Dosimetrists.
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INTRODUCTION
Malignant mesothelioma is a very serious disease. The
contemporary treatment in operable cases involves a
combination of neoadjuvant chemotherapy (Cisplatinum,
Premetrex), extrapleural pneumonectomy, and postoper-
ative radical radiation therapy. In these patients, newer
intensity modulated radiation therapy (IMRT) techniques
are used to achieve a better therapeutic ratio.1,2 However,
the majority of cases (70–80%) are inoperable and often
require palliative radiation therapy.3 Clinical use of he-
lical tomotherapy (HT) has not been reported in these
situations.
Escalating the prescribed radiation dose to the plan-
ning target volume (PTV) improves the likelihood of
tumor control and long-term survival, but is limited by
the tolerance doses of nearby organs at risk (OARs).4,5
To raise the tumor dose without increasing the risk of
normal-tissue toxicity, precise delivery and verification
systems such as step-and-shoot IMRT, CyberKnife, and
HT have been developed.6–10
HT is composed of a 6-MeV linear accelerator
mounted on a ring gantry, with radiation delivered to the
patient in a helical fashion. A 64-leaf collimator allows
for a dynamically adjustable intensity profile.11,12 In
addition to delivering highly conformal radiation dose
distributions, HT is equipped with xenon detectors de-
signed to obtain megavoltage computed tomography
(MVCT) image sets of the patient prior to treatment.13
Radiation therapists co-register these MVCT studies
with planning kilovoltage CT (kVCT) studies to cor-
rectly position the patient, thereby minimizing setup
error. Pretreatment MVCT imaging provides enough soft
tissue contrast to reliably delineate organs and lesions,
enabling clinicians to monitor interfraction variations in
patient anatomy. The quantification of tumor regression
occurring during radiotherapy in lung cancer patients is
well documented.4,14–17 Varying degrees of shrinkage
have been observed, but in all cases, as a tumor decreases
in volume, healthy tissue that takes its place is unneces-
sarily irradiated to the prescription dose. Plan adaptation
to these anatomy changes may significantly improve a
patient’s treatment.18 Woodford et al. have related the
potential benefit of image-guided adaptive radiotherapy
to changes in gross tumor volume (GTV). They found
that regression patterns could be broadly divided into 3
groups and that adaptive planning would be most appro-
priate when the GTV decreases by greater than 30% at
any point in the first 20 fractions of treatment.17
In some cases, tumors exhibit resistance to treat-
ment, and no clear trend toward a decrease in volume is
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observed. This reduced radiosensitivity in some tumor
cells may be the result of several factors, one of which is
the ‘hypoxia effect.’19 Tumors have deficient vascular
systems and as such, contain hypoxic cells, which sur-
vive in nutrient-deprived and low oxygen conditions and
have a characteristically low sensitivity to radiation lev-
els. Their presence significantly hinders GTV regression
and negatively influences prognosis.19
Because of potentially delayed responses, adaptive
radiotherapy may offer little benefit to these types of
resistive tumors. If, however, the margins defining the
PTV are reduced, a new and improved plan may be
created. PTV margins encompass intrafractional motion
and setup uncertainty; they also cover the clinical tar-
get volume, which serves to ensure the sterilization of
any subclinical microscopic extensions surrounding the
GTV. To avoid the risk of disease recurrence, PTV
margin reduction can only be safely accomplished at a
point when sufficient radiation has been delivered to
eliminate invisible microscopic spread. Two possible
treatment strategies can be followed after adapting a
radiotherapy plan with reduced PTV margins. The first is
to reduce healthy tissue irradiation as much as possible
while leaving the prescription dose to the target volume
unchanged. The second choice is to escalate the dose to
the tumor as high as possible while not surpassing the
levels of healthy tissue irradiation achieved in the initial
plan. The aim of this study is to demonstrate the potential
benefits of adaptive radiation therapy by describing a
case of mesothelioma with mediastinal metastasis treated
using helical tomotherapy. This study evaluates dosimet-
ric planning and tumor volume changes observed on
MVCT studies. By using the Planned Adaptive software
(TomoTherapy Inc., Madison, WI) to delineate targets
and sensitive structures, PTV margins were appropriately
reduced, and adapted plans for both treatment strategies
were generated. The study quantifies volumetric and
dosimetric changes, examines the effects of the adapted
plans, and compares them to the original plan. Plans
created using alternative treatment modalities (3D con-
formal radiation therapy [3DCRT] and step-and-shoot
IMRT) are also evaluated and compared to original HT
plans.
METHODS AND MATERIALS
A 73-year-old female patient with history of prior
exposure to asbestos presented with symptomatic bi-
phasic mesothelioma of the right lobe pleura and a me-
diastinal mass. The patient had a previous renal lesion 2
years prior, which was stable. Pulmonary function tests
were normal. A biopsy sample showed it as a malignant
mesothelioma. By the T3N2M0 staging and surgical
assessment based on a computed tomography (CT) scan,
the disease was confirmed as inoperable. The patient did
not receive any chemotherapy and it was decided to give
radiotherapy as treatment. A kVCT study (Fig. 1a) was
Fig. 1. (a) kVCT image taken 9 days before treatment began.
MVCT image acquired prior to (b) 1st fraction and (c) 22nd
fraction. GTV2 (green), GTV1 (white), PTV2 (purple), PTV1
(red), ipsilateral (light green), contralateral lungs (light blue),
and spinal cord (yellow) are outlined. Long-term volume re-
gression is most notable in GTV1.
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taken 9 days before the start of treatment on a helical CT
scanner (Philips Brilliance Big Bore, 3-mm-slice thick-
ness, 120 kVp). The radiation oncologist (ARD) outlined
2 targets (mediastinal nodal GTV2, pleural lesion GTV1)
and the following sensitive structures using the Pinnacle
treatment-planning system (Pinnacle3 version 8.0d; Phil-
ips, Fitchburg, WI): lungs, spinal cord, and heart. All
critical structures were assumed to be solid organs for
dosimetric purposes. Ipsilateral lung was defined as lung
minus both GTVs. GTV2was delineated with the inten-
tion of including affected mediastinal lymph nodes. Plan-
ning target volumes were created by 5 mm (PTV1) and
10 mm (PTV2) 3D isotropic margins around GTV1 and
GTV2, respectively. Clinical target volumes (CTVs)
were defined equal to the PTVs. Initial recorded volumes
were 228.4 cm3 for GTV2 and 15.2 cm3 for GTV1. Doses
of 50 Gy to GTV2 and 60 Gy to GTV1 were prescribed
in 30 fractions. The patient received 22 fractions, after
which, treatment was stopped due to a non-treatment–
related arm fracture. A repeat kVCT scan 3 months after
the last radiotherapy fraction and clinical examination
showed no radiation complications of either the lungs or
esophagus, but there was a residual mediastinal nodal
disease.
Helical tomotherapy planning
CT and structure datasets were transferred to the
Tomotherapy Hi-ART planning station (version 2.2.2,
TomoTherapy Inc., Madison, WI) using the DICOM RT
protocol. Control of dose delivery is achieved through 3
parameters: fan-beam thickness, pitch, and modulation
factor, described in detail elsewhere.11 For all tomo-
therapy plans in this study, the fan-beam thickness was
set to 5.02 cm, with a pitch of 0.287, and a maximum
modulation factor of 3. Dose calculation grid was ap-
proximately 4  4  3 mm.3 Optimization was guided
using precedence, importance, and penalty factor param-
eters, as illustrated in Table 1. Coverage of 95% of the
PTVs was set as the optimization target in each plan.
Desired dosimetric constraints were Dmax for the spinal
cord (46 Gy), D30 to the heart (45 Gy), as well as
combined mean lung dose (20 Gy). About 200 iterations
were used in the optimization procedure for each plan
after beamlet calculation, with the total planning time
(range: 2–4 hours) depending on the PTV volume. The
HT plan based on initial anatomy from the kVCT study
(plan 1: expected beam-on time: 220.6 seconds per frac-
tion) was approved for treatment.
Delineation of structures
Daily MVCT studies (Fig. 1b and 1c) were acquired
preceding each treatment and were transferred to the
planning station. GTVs and OAR contours were adapted
for all treatment days using Planned Adaptive to assess
volumetric and dosimetric variations. Absolute volumes
of the GTVs, as well as D1 and D99 for the PTVs, were
recorded. Dx denotes dose to x% of the structure’s vol-
ume. Additionally, absolute volume, V5, V10, V20, and
V30 were tabulated for both the contralateral and ipsilat-
eral lungs. Vy means relative volume of the structure
irradiated to y Gy or more. To assess the intraobserver
contouring uncertainty, contour adaptation was twice
repeated to include both the largest and smallest imag-
inable GTV volumes on the 1st, 11th, and 23rd fractions.
Interpolation of volumetric discrepancies between these
days was assumed to be linear.
Reducing healthy tissue irradiation
After 22 fractions, the MVCT studies showed ob-
servable volume reduction in both GTVs. At this point, it
was assumed that the subclinical microscopic disease of
the target volumes had been sterilized allowing for safe
reduction of both PTV margins to 4 mm. Our hypothesis
is that microscopic tumor spread is relatively more radi-
osensitive and well oxygenated, so that likelihood of
these tumor cells survival and/or regrowth is very low
after irradiation during 22 fractions (2 Gy/fraction).
These reduced margins would be sufficient to account for
post image-guided alignment setup errors and intrafrac-
tion movement. An adapted plan with updated structure
outlines to reflect the anatomy changes was generated
using the MVCT study taken on the 22nd fraction (plan
2: beam-on time 229.0 seconds). All optimization param-
eters were left unchanged from plan 1 for comparative
purposes. This plan represented the first of the 2 treat-
ment strategies; it kept the original prescribed dose to the
targets and reduced the critical organ dose.
Escalating dose
A third plan reflecting the second strategy, that is, to
increase the target dose while maintaining the same level
of healthy tissue sparing achieved in plan 1, was also
created (plan 3: beam-on time 256.6 seconds). The same
structure and image sets as in plan 2 were used. Increased
prescription doses were determined as follows: in plan 1,
the percentage of ipsilateral lung receiving 20 Gy or
more V20 was approximately 80.5% and, in plan 2, the
same percentage was receiving about 17 Gy. The ratio of
these values (1.175) was applied as a scaling factor to
the original PTV doses. The intent was to generate a plan
in which the ipsilateral lung V20 was equivalent to that of
plan 1. The choice of V20 as a reference point was based
Table 1. Optimization parameters for plan 1
Structure Importance
Max
Dose
(Gy)
Max
Dose
Penalty
DVH
Volume
(%)
DVH
Dose
(Gy)
DVH
Pt.
Penalty
Spinal cord 1 44 1 1 43 1
Right lung 1 60 1 17 40 1
Left lung 10 50 1 15 5 33
Heart 1 50 1 30 30 1
PTV1 10 60 1 95 50 33
PTV2 10 50 1 95 60 33
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upon its clinical significance as a risk indicator for acute
toxicity development.20 With the exception of the spi-
nal cord, dose constraint parameters used by the plan-
ning software were also scaled by the same value. The
spinal cord exceeded its clinically accepted maximum
dose when scaled; therefore, it was left unchanged
from plan 1.
Dose quality factor
As lung cancer is one of the more difficult diseases
to treat with radiotherapy, it is advantageous to compare
different available radiation delivery modalities. Plan 1
was reproduced using both step-and-shoot IMRT and
3DCRT. These alternative solutions were subsequently
compared to HT using a dose quality factor (DQF)
scoring option. The DQF is a single value assigned to
each treatment plan based on a balanced scoring sch-
eme for target coverage and normal tissue sparing.21 It is
defined as:
DQFDQFtarget  DQFOAR (1)
DQF for target and OAR calculations are based on
the acceptable dose (Dacc) as well as the actually
achieved dose (D) for selected sub-volumes:
DQFtarget  wi DDacc
n
i
(2)
DQFOAR  wjDaccD nj (3)
where w is the weighting for a specific structure and i and
j are indices that sum over all targets and OARs, respec-
tively. The sum over all weighting factors is one. For
the DQF(target), D/Dacc is set to unity if D Dacc. In the
case of DQF(OAR), the same is done if D  Dacc. The
exponent n, in Eqs. (2) and (3), allows for different dose
levels to have differently assigned importance factors.
Table 2 lists the acceptable doses, subvolumes, weight-
ing factors, and values of n used in this comparative
planning study for each structure. These values have
been chosen based on the relative importance of meeting
the required dose for different structures, as seen through
clinical experience.21
RESULTS AND DISCUSSION
In this study, initial (and clinically applied) plan 1
and two “adapted” treatment plans, one aimed to im-
prove OAR sparing (plan 2) and another to escalate
target dose (plan 3), were generated. Dose-volume his-
tograms (DVHs) were analyzed to compare different
possible treatment options and are shown in Fig. 2.
Sensitive structure tolerance dose limits were met for the
heart in all plans, for the lungs in plans 2 and 3, and for
the spinal cord in plan 2 (Table 3). In plan 1, combined
mean lung dose (MLD) was 20.22 Gy. This high dose to
the lungs is due to this patient’s specific anatomy, with 2
targets far apart and HT’s helical mode of radiation
delivery. PTV2 is very close to the spinal cord and only
the reduction of PTV margins in plan 2 could effectively
decrease the cord’s Dmax below 46 Gy.
Plan 2 (improved OAR sparing)
PTV2 was reduced from 595 to 320 cm3 and PTV1
from 45.8 to 25.4 cm3 after 22 fractions. The percent-
age of ipsilateral lung V20 was reduced by 7.9% in
plan 2. Similarly, planned mean dose delivered to the
ipsilateral lung was decreased from 34.1 to 28.5 Gy.
The planned combined lung MLD decreased by 3.93
Gy and V20 by 5.4%. Because this plan would be
applied to the final 8 fractions of treatment only,
combined lung MLD is actually lowered by 1.05 Gy
and V20 by 1.4%. Dose distributions for plans 1 and 2
are shown in Figs. 3 and 4, respectively. Both plans
demonstrate high conformality of the 50 and 60 Gy
isodose lines to their respective target contours. Figure
5 shows a comparison of DVHs for plans 1 and 2. For
all OARs, the sparing of healthy tissue is improved in
plan 2 (most notably for the ipsilateral lung), while
providing a comparable target volume coverage.
Plan 3 (escalated prescription dose)
Prescribed doses to PTV2 and PTV1 were scaled by a
factor of 1.175, increasing them from 50 and 60 Gy to 58.75
Table 2. Parameters used for calculation of the dose quality factor
Parameter
Acceptable Dose Level
(Gy) Subvolume (%) Weighting n
Target 1 PTV2 minimum dose 43.7a 99 0.4 1
Target 2 PTV1 minimum dose 57.0a 99 0.4 2
Target 3 PTV1 prescription 60.0 95 0.15 1
Target 4 PTV1 maximum dose 64.2b 1 0.05 1
OAR 1 Mean lung dose 20.0 n/a 0.4 1
OAR 2 Spinal cord Dmax 46.0 0 0.4 2
OAR 3 Heart D30 45.0 30 0.1 1
OAR 4 Esophagus D1 60.0 1 0.1 1
aPrescription dose minus 5%.
bPrescription dose plus 7%.
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and 70.5 Gy, respectively. This approach aimed to
increase the prescribed dose to achieve the same ipsi-
lateral lung V20 value as in plan 1. Our calculation of
V20 value for plan 3 resulted in 77.8%, 3.7% less than
the original plan 1. If the plan were applied to the
remaining 8 fractions, then the dose to PTV2 and PTV1
would be increased to 52.3 and 62.8 Gy, respectively.
Martel et al.22 estimated the effects of total radiation
dose on probability of tumor control and found that
when 65 Gy was delivered, 53% and 26% of patients
experienced local progression-free survival after 12
Fig. 2. (a) DVH of plan 1 for HT delivery. Color code: dark
blue ipsilateral lung; light blue contralateral lung; green
heart; orange  spinal cord; red  GTV2; pink  PTV2;
grey  GTV1; black  PTV1. (b) DVH of plan 2. (c) DVH of
plan 3.
Fig. 3. Dose distribution (a) axial and (b) sagittal produced for
plan 1 on the 33rd day of treatment. (c) Color code for isodose
lines.
Table 3. Summary of tomotherapy plans
Plan
PTV2 PTV1 Lungs
Cord Dmax (Gy) Heart D30 (Gy)D99 (Gy) D1 (Gy) D99 (Gy) D1 (Gy) V20 (%) MLD (Gy)
1 47.37 55.36 59.97 62.56 43.51 20.22 49.11 28.87
2 47.45 55.02 59.86 61.64 38.12 16.29 45.18 24.42
3 56.04 65.24 70.49 72.69 40.55 19.07 49.23 28.06
Abbreviations: MLD, mean lung dose; DX, dose to x% of the organ volume; V20, relative volume exposed to 20-Gy dose; Dmax, maximum dose to organ.
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and 30 months, respectively. Examining the dosimet-
ric data set of plan 3 reveals a general improvement in
healthy lung sparing, despite the increase doses to
targets due to the decreased target margins. The MLD
and V20 for both lungs are 5.7% and 6.8% lower than
in the original plan. Prescription isodose lines again
conform nicely to the target volumes, as seen in Fig. 6.
Relative homogeneity of dose distributions for both
target volumes is achieved. In this case, the proximity
of the heart was the limiting factor for dose escalation.
Due to the heart’s slight overlap with the GTV, its
Dmax was raised to 60.3 Gy in plan 3. Had the posi-
tioning of the heart not been an issue, further escala-
tion of the prescribed doses could have been poten-
tially feasible. The escalation of dose presents an issue
in fractionation that needs to be addressed. One option
is to increase number of fractions needed to deliver
this dose proportionally, keeping the dose per fraction
unchanged from the original plan. The other possibil-
ity would be to keep the existing number of remaining
fractions and increase the dose per fraction. The bio-
logical effect of these options is not the same and, in
fact, reducing the overall treatment time has been
shown to have favorable effects on survival. Saunders
et al.23 performed a study comparing accelerated vs.
conventional radiotherapy in patients with non-small
cell lung cancer and found that the accelerated patients
showed improved survival rates (63% vs. 55% after 1
year, 29% vs. 20% after 2 years, and 20% vs. 13%
after 3 years).
Tumor regression
A total of 23 MVCT imaging sessions were per-
formed over the span of 36 days. During that time,
there was a 16.2% and 32.5% measured volume re-
duction in GTV2 and GTV1, respectively. Relative
changes in GTV2 and GTV1 over the course of treat-
ment are presented in Fig. 7. Mean volume change per
day for the GTV2 was 0.7%  3.5%, with a range of
7.5% to 7.8% change per day. For GTV1, the mean
volume change was 2.0%  10.9%, with a range of
25% to 27% change per day. In both cases, tumor
regression was generally a very slow process, with no
periods of accelerated decreasing. If these results are
similar to the results of Woodford et al., GTV1 would
fall into group B (a more gradual linearly decreasing
tumor volume), whereas GTV2 would most likely fall
into group C (experienced variable volume changes
with no clear trend toward a decrease in volume).17
This information on tumor regression does not imply
that regression will stop once the therapy is through.
In fact, it is shown that NSCLC tumors reach their
Fig. 4. (a) Axial and (b) sagittal dose distributions that would
have been produced for plan 2 on the 33rd day of treatment.
(c) Color code for isodose lines.
Fig. 5. DVH of plan 1 and plan 2. Lines from plan 1 have black
circles on them. It is clear that plan 2 spares more healthy tissue
while providing virtually the same target coverage. Color code:
dark blue  ipsilateral lung; light blue  contralateral lung;
green  heart; orange  spinal cord; grey  GTV2; pink 
PTV2; black  GTV1; red  PTV1.
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minimum volume, on average, 11 months after radia-
tion completion.24 According to classification of tu-
mor regression proposed by Siker et al., the responses
of both GTVs would be stable (0 –34% regression).4
Applying these criteria to the observed GTV changes
on HT by several groups,4,16,17 the frequency of stable
responses vary. In 2 data sets, Siker et al. reported
68% and 53% of patients having stable tumor re-
sponses, whereas Woodford et al. similarly observed
41%.4,17 This contrasts the work of Kupelian et al.,
who reported no stable responses in any patients.16
Contouring uncertainty
With each slice reconstructed from a 5-second
data acquisition, MVCT is a “slow” CT scan, with
some averaging of moving objects. Tumor volume and
position uncertainty is directly related to the patient’s
breathing cycle, which, in turn, is largely dependant
upon the level of comfort.25 A large amount of uncer-
tainty in delineating GTV2 was associated with it
being primarily contained within the mediastinum.26
The MVCT image sets used to contour GTV2 did not
have sufficient contrast and resolution to reliably adapt
the contours contained within the mediastinum. GTV1,
on the other hand, is considered to be a peripheral-
lung tumor and it was easily detected and delineated
on the MVCT image sets.26
Patient positioning
In addition to the detection of any significant
interfraction anatomy changes, such as tumor regres-
sion or position shift, MVCT studies enable the cor-
rection of patient positioning just prior to treatment.
Throughout this patient treatment, the average posi-
tioning corrections (in mm) in the x (lateral),
y (superior-inferior), and z (anterior-posterior) direc-
tions were 2.7  2.7, 0.8  2.9, and 8.0  3.2,
respectively. There are several factors that may influ-
ence the position correction. This patient experienced
significant weight loss over the course of treatment.
External marking tattoos used for initial setup were
most likely displaced with respect to the internal or-
gans. Also, pain and difficulty in breathing often pre-
Fig. 6. (a) Axial and (b) sagittal dose distributions that would
have been produced for plan 3 on the 33rd day of treatment.
(c) Color code for isodose lines.
Fig. 7. (a) Relative GTV2 and (b) GTV1 volumes recorded over
the course of treatment.
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vent patients from keeping their hands up over their
head in the same position, as required during treat-
ment. In the z direction, the average positional shift is
around 8 mm. This can be explained by the mechanical
differences in the planning kVCT and the MVCT
couches; the latter is more flexible. The corrective shifts in
the y direction alternate from negative to positive over the
course of treatment with respect to zero. The average shift
in the lateral direction is due to the GTV changes most
prominent in this direction.
Step-and-shoot IMRT plan for this patient
A step-and-shoot IMRT plan was created with the
Pinnacle planning system for the same planning kVCT
study and organ contours and was compared to the
original HT plan. Three 6-MV beams and two 18-MV
beams were chosen to achieve a reasonable coverage
of the target volumes while avoiding OAR irradiation
as much as possible. The dose distribution and DVH
curves for the step-and-shoot IMRT plan are shown in
Fig. 8 (a) and (c). An examination of the DVHs reveals
an overall improvement in healthy tissue sparing over
the original HT plan. Significant gains include the
heart D30 being reduced to 11.5 Gy (HT plan: 28.9
Gy), combined lung V20 and MLD lowered to 33.3%
and 19.8 Gy (HT plan: 43.5% and 20.2 Gy), and Dmax
to the spinal cord decreased to 47.2 Gy (HT plan: 49.1
Gy). Consequently, this plan has a better DQF(OAR)
(see Eq. [3]) score than HT (0.958 vs. 0.938). How-
ever, an examination of target coverage shows that the
step-and-shoot IMRT plan does not deliver as confor-
mal a dose distribution as does HT. This is exemplified
in D99 and D95 values for both of the targets. The HT
plan delivered 59.3 and 59.9 Gy to 99% and 95% of
PTV1, respectively, whereas corresponding step-and-
shoot IMRT plan values were lower—53.8 and 57.1
Gy. Furthermore, 99% of PTV2received 39.7 Gy using
the step-and-shoot IMRT plan, much lower than the
45.5 Gy provided by HT. Due to the scoring scheme’s
heavy weighting of the target D99 statistic, step-and-
shoot IMRT’s DQF(target) score is notably lower than
that of HT (0.883 vs. 0.983). Overall DQF scores place
Fig. 8. (a) Axial dose distribution that would have been pro-
duced by radiation fluence of the step-and-shoot IMRT version
of plan 1. (b) Color code for isodose lines. (c) DVH of step-
and-shoot IMRT plan. Color code: light blue ipsilateral lung;
dark blue  contralateral lung; red  heart; orange  spinal
cord; red  GTV2; purple  PTV2; brown  GTV1; yellow 
PTV1.
Fig. 9. (a) Axial dose distribution that would have been pro-
duced by radiation fluence of the 3DCRT version of plan 1.
(b) Color code for isodose lines. (c) DVH of 3DCRT plan.
Colour code: light blue  ipsilateral lung; dark blue  con-
tralateral lung; red heart; orange spinal cord; red GTV2;
purple  PTV2; brown  GTV1; yellow  PTV1.
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HT (0.922) as a more appropriate treatment solution
when compared to the step-and-shoot IMRT plan
(0.847).
3DCRT plan for this patient
The Pinnacle planning system was also used to
create a 3DCRT plan. Planning with this modality was
particularly challenging due to the geometry of the 2
separate targets. When two 6-MV and four 18-MV
beams were initially orientated to achieve a reasonable
coverage of both PTVs, some critical structures recei-
ved clinically unacceptable levels of irradiation. Im-
provement for healthy tissue sparing was accom-
plished through the use of physical wedges as beam
attenuators. The achieved dose distribution and DVH
curves are shown in Fig. 9 (a) and (c). Target coverage
is comparable and, in some cases, slightly improved
over the HT plan, especially for PTV2. Using 3DCRT,
99% of PTV2 would receive 55.1 Gy compared to 45.5
Gy in the HT plan. The DQF(target) for the 3DCRT
plan (0.996) is therefore slightly better than HT plan 1
(0.983). Healthy tissue sparing offered by both mo-
dalities is, for the most part, also quite comparable.
Using 3DCRT, combined lung MLD is slightly higher
at 21.4 Gy (HT plan: 20.2 Gy), combined lung V20 is
lowered to 38.1 % (HT plan: 43.5%), and D30 for the
heart is significantly reduced to 13.2 Gy (HT plan:
28.9 Gy). However, a maximum spinal cord dose of
56.7 Gy (HT plan: 49.1 Gy) is too high to be clinically
acceptable. Large exiting doses from the beam cover-
ing PTV1 were received by the cord. Relatively heavy
weighting of the spinal cord gave 3DCRT a DQF(OAR)
score of 0.862, and an overall DQF score of 0.859. In
general, due to the complex target geometry of this case,
3DCRT would not be clinically appropriate without de-
creasing PTV prescription doses by about 10 Gy to decrease
spinal cord irradiation to acceptable levels. Table 4 sum-
marizes the dosimetric parameters used to determine DQF
scores.
CONCLUSIONS
Daily MVCT studies provide information for pa-
tient setup correction, which can be used to decrease the
PTV margins even before the treatment starts. Further
plan improvement can be achieved if the target exhibits
a volume reduction as a result of radiation delivery,
which should be significant enough to warrant a replan-
ning. The choice of specific adaptation strategy (in our
case, dose escalation or improved sparing) is related to
the specific anatomy of a particular patient. Daily imag-
ing is not exclusive to HT; alternative treatment modal-
ities such as step-and-shoot IMRT equipped with cone
beam CT may provide similar adaptive capabilities. As a
result, more comparative planning for a larger patient
database should be done to establish guidelines for pref-
erential usage of HT or traditional linear accelerators.
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